The UK's largest event for private investors

Business Design Centre, London, 29 March 2025








Ananda Developments Plc logo

Ananda Developments Plc

Ananda’s mission is to be a leading provider of cannabis-based medicines for the treatment of complex, chronic inflammatory pain conditions.

The world has an increasing problem with chronic pain conditions such as fibromyalgia, neuropathic pain, rheumatology, endometriosis and epilepsy.

The NHS spends more than £5 billion per year treating chronic pain conditions, and the global anti-inflammatory drugs market is projected to reach US$191.42 billion by 2027. Treatments for these conditions are often expensive, invasive or have negative side effects. There is growing evidence demonstrating that cannabis and its constituents are very good at treating these complex chronic inflammatory pain conditions.

Ananda’s patent pending MRX medicines are being used in two Phase 2 randomised controlled clinical trials, both of which are being funded by third parties. One is for chemotherapy induced pain and the other is for endometriosis. Ananda’s objective is to get these medicines available on the NHS.

Ticker: AQSE:ANA

Get your ticket

Don't miss out on the UK's largest event for private investors - secure your ticket today.